InvestorsHub Logo
Followers 1371
Posts 72672
Boards Moderated 1
Alias Born 08/20/2007

Re: $heff post# 83675

Wednesday, 10/29/2014 10:47:37 AM

Wednesday, October 29, 2014 10:47:37 AM

Post# of 97237
ELTP, 23K bid @ .32, maybe we will hearing more positive news soon. Latest news:

Elite Pharmaceuticals Announces New Management Appointments
7:15a ET October 24, 2014 (GlobeNewswire) Print


Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Property for Sanofi Aventis. In both positions, Dr. Smith had global responsibility for all intellectual property issues related to multiple business units involved with various technologies including branded products, animal health products, active pharmaceutical ingredients, generic drugs, and vaccines. Dr. Smith also brings extensive background and knowledge in the area of abuse deterrent intellectual property. Dr. Smith has a Ph.D. in Biochemistry from University of Houston, an M.B.A from Lehigh University, and a J.D. from the University of Houston.

Dr. LePree joins Elite with a wealth of experience in formulations and analytical research and development having most recently severed as the Principal Scientist, Formulations Research and Development for Capsugel. Dr. LePree also held previous positions in research and development with Abon Pharmaceuticals, Penwest Pharmaceuticals, Novartis, and Hoffman-LaRoche. Dr. LePree has a B.S. in Pharmacy from Rutgers University and a Ph.D. in Pharmacy from the University of Wisconsin. He is also an Adjunct Professor of Pharmacy at Long Island University.

Dr. Abraham brings to Elite extensive regulatory and analytical experience having worked for over 20 years at Teva Pharmaceuticals. Her most recent position at Teva was Senior Regulatory Associate. Dr. Abraham has B.S. in Zoology, Botany, and Chemistry from the University of Kerala, India and a Ph.D. in Zoology from the University of Baroda, India.

"We are pleased to welcome Ken, Jason and Sophy to the Elite team and I'm thrilled with the caliber of expertise that these individuals bring to Elite," said Nasrat Hakim, Elite's President and Chief Executive Officer. "These additions greatly strengthen our management team in key areas and enhance our internal expertise in product development, regulatory compliance and intellectual property to support the development of our opioid abuse deterrent products."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.